3Scan raises $14 million in latest round of funding

3Scan, a San Francisco-based pathology technology company focused on the imaging of tissue samples, announced this week it has raised $14 million in Series B financing. The funding was led by existing investors Lux Capital and Data Collective, with additional funding from Dolby Family Ventures, OS Fund, Comet Labs and Breakout Ventures.

The funding will go toward improving 3Scan’s standing in the marketplace while also allowing the company to continue developing new technology.

“In the last 150 years, very little has changed in the tools available to pathologists and researchers who examine tissue,” Todd Huffman, 3Scan CEO and co-founder, said in a prepared statement. “We are working on demonstrating the importance of comprehensive 3-D spatial mapping of tissue samples. 3Scan has already secured service contracts with several large pharma companies in order to help them image and refine drug delivery to solid tumor cancers in mice (where drugs are often tested before entering clinical trials and being tested in humans).”

“3Scan’s automated histology platform fills the gap between radiology and pathology by allowing large-volume high-throughput imaging of tissue and tissue scale diseases,” Megan Klimen, 3Scan COO and co-founder, said in the same statement. “This type of imaging technology is essential if ever want to be able to use the power of modern computing to improve pathology outcomes.”